Expression of CCAAT/enhancer binding protein beta in human gastric carcinoma and its clinical significance.
- Author:
Yun-xia DU
1
;
Lian-hai ZHANG
;
Xiao-hong WANG
;
Xiao-fang XING
;
Xiao-jing CHENG
;
Hong DU
;
Ying HU
;
Ying-ai LI
;
Yu-bing ZHU
;
Yong-ning JIA
;
Yi LIN
;
Jia-fu JI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; CCAAT-Enhancer-Binding Protein-beta; metabolism; Female; Gastric Mucosa; metabolism; pathology; Humans; Male; Middle Aged; Prognosis; Stomach Neoplasms; metabolism; pathology
- From: Chinese Journal of Gastrointestinal Surgery 2013;16(2):179-182
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the expression of CCAAT/enhancer binding protein beta (CEBPB) in gastric carcinoma tissues and its association with clinicopathological features and prognosis.
METHODSCEBPB protein expression level was detected by immunohistochemistry method in resected gastric carcinomas and adjacent gastric mucosa tissues (n=81), and its association with clinicopathological features and prognosis was analyzed.
RESULTSThe immunohistochemical staining of CEBPB was predominantly in the nucleus with some cytoplasmic staining. As a result, 16% (13/81) of the gastric carcinomas were stained positively, whereas there was hardly positive expression in adjacent gastric mucosa tissues. There was a significant association between the expression of CEBPB and distant metastasis on univariate analysis (P<0.05). The median survival time in patients with positive CEBPB expression was significantly lower than those with negative CEBPB expression (19.4 months vs. 45.2 months, P=0.024). Multivariable analysis showed that CEBPB was independently associated with prognosis (HR=2.544, 95%CI:1.154-5.610, P=0.021).
CONCLUSIONUp-regulation of CEBPB suggests poor prognosis in patients with gastric cancer.
